Post-CA Neuroprotection With Magnesium
Neuroprotection Following Cardiac Arrest: A Randomized Control Trial of Magnesium
NYU Langone Health
178 participants
Mar 25, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this pilot interventional study is to collect preliminary data on administering magnesium sulfate as a neuroprotective medication in patients who achieved Return of Spontaneous Circulation (ROSC) following Cardiac Arrest (CA). The primary aims are to assess the feasibility and safety of administering magnesium and measure serum markers of neuronal injury at prespecified time points in the post-cardiac arrest period. Because this is a pilot study with a limited sample size, the primary objective is to evaluate the precision and stability of the collected measures to inform the design and formal analysis in a larger trial.
Eligibility
Inclusion Criteria1
- Documented post-cardiac arrest patient with Return of Spontaneous Circulation (ROSC) achieved <2 hours prior to recruitment
Exclusion Criteria8
- Age < 18 years or > 85 years
- Traumatic cardiac arrests
- Unsustained ROSC (<20 minutes)
- Patient who is responsive/able to follow motor commands within 1 hour of achieving ROSC
- Plan for withdrawal of life support within 72 hours of ROSC
- Known pregnant women at the time of the cardiac arrest
- Known prisoners at the time of the cardiac arrest
- Subjects who have a medical o social condition that would make them inappropriate for the study based on the PI's or clinical team judgement.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
4 g of magnesium sulfate intravenously within 2 hours of Return of Spontaneous Circulation (ROSC), followed by a continuous drip (16 g) over 24 hours
Control subjects will receive an equivalent volume of normal saline intravenously.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06455514